Dr. Robert Z Orlowski on the Importance of the Phase III SWOG S0777 Trial
Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.
Robert Z Orlowski, MD, PhD, professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, on the importance of the SWOG S0777 trial. Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.
Orlowski says oncologists have been using a combination of bortezomib, lenalidomide, and dexamethasone for years as thede factofrontline treatment, despite phase III trial data was not present. He says this is important for oncologists because the triplet now joins the Category 1 recommendation level from the National Comprehensive Cancer Network.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
